{"id":355059,"date":"2026-11-19T13:57:26","date_gmt":"2026-11-19T08:27:26","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=355059"},"modified":"2026-11-19T13:57:26","modified_gmt":"2026-11-19T08:27:26","slug":"alembic-pharma-analyst-review","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/alembic-pharma-analyst-review\/","title":{"rendered":"Alembic Pharma Analyst Review 2027: Profit Up 81% and Guidance Raised, Stock Runs Past Targets"},"content":{"rendered":"<div style=\"background:#E8F1FF;border-left:5px solid #1565C0;padding:16px 20px;margin:0 0 20px 0;border-radius:6px;\">\n<p><strong>Alembic Pharmaceuticals Stock Snapshot (18 Nov 2026 close)<\/strong><\/p>\n<ul>\n<li><strong>Current Market Price (CMP):<\/strong> \u20b91,044.35<\/li>\n<li><strong>52-Week High \/ Low:<\/strong> \u20b91,075.00 \/ \u20b9635.80<\/li>\n<li><strong>Market Capitalisation:<\/strong> \u20b920,512 crore<\/li>\n<li><strong>P\/E Ratio vs Industry P\/E:<\/strong> 24.4 vs 40.1<\/li>\n<li><strong>Latest Quarter (Q2 FY27) Revenue:<\/strong> \u20b92,603 crore<\/li>\n<li><strong>Latest Quarter (Q2 FY27) Net Profit:<\/strong> \u20b9335 crore<\/li>\n<\/ul>\n<\/div>\n<div style=\"background:#F0F9FF;border-left:5px solid #2E7D32;padding:16px 20px;margin:0 0 20px 0;\">\n<p><strong>Quick Answer:<\/strong> The <strong>Alembic Pharma analyst review 2027<\/strong> shows a blowout quarter that pushed the stock past the last named target. Q2 FY27 revenue rose 36% to \u20b92,603 crore and profit rose 81% to \u20b9335 crore, with EBITDA margin up to 22% from 17%. US sales jumped 77% to \u20b9910 crore and management raised FY27 revenue growth guidance to 20% to 25%. Motilal Oswal&#8217;s Neutral call with an \u20b9845 target (August 2026) is now about 19% below the \u20b91,044.35 price, so the <strong>Alembic Pharma share price target 2027<\/strong> picture needs fresh broker updates.<\/p>\n<\/div>\n<p>The <strong>Alembic Pharma analyst review 2027<\/strong> covers Alembic Pharmaceuticals, a Vadodara-based drug maker that sells generics in the US, branded medicines in India, active pharmaceutical ingredients and products in other export markets. Readers looking for an <strong>Alembic Pharma share price target 2027<\/strong> should note that the stock rallied about 20% in a single day after the results.<\/p>\n<p><a href=\"https:\/\/univest.in\/stocks\/aplltd\/alembic-pharmaceuticals-ltd-share-price-today\">Alembic Pharmaceuticals<\/a> closed at \u20b91,044.35 on 18 November 2026, about 3% below its 52-week high of \u20b91,075 and about 64% above its low of \u20b9635.80. This Alembic Pharma analyst review 2027 covers the results, the guidance change and the <strong>Alembic Pharma stock outlook 2027<\/strong>.<\/p>\n<p><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=alembic-pharma-analyst-review\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-analyst-review\/#What_Brokerages_Say_in_the_Alembic_Pharma_Analyst_Review_2027\" title=\"What Brokerages Say in the Alembic Pharma Analyst Review 2027\">What Brokerages Say in the Alembic Pharma Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-analyst-review\/#Q2_FY27_Results_in_the_Alembic_Pharma_Analyst_Review_2027\" title=\"Q2 FY27 Results in the Alembic Pharma Analyst Review 2027\">Q2 FY27 Results in the Alembic Pharma Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-analyst-review\/#How_Alembic_Pharma_Makes_Money\" title=\"How Alembic Pharma Makes Money\">How Alembic Pharma Makes Money<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-analyst-review\/#Growth_Triggers_in_the_Alembic_Pharma_Analyst_Review_2027\" title=\"Growth Triggers in the Alembic Pharma Analyst Review 2027\">Growth Triggers in the Alembic Pharma Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-analyst-review\/#Key_Risks_in_the_Alembic_Pharma_Analyst_Review_2027\" title=\"Key Risks in the Alembic Pharma Analyst Review 2027\">Key Risks in the Alembic Pharma Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-analyst-review\/#Alembic_Pharma_Analyst_Review_2027_Stock_at_a_Glance\" title=\"Alembic Pharma Analyst Review 2027: Stock at a Glance\">Alembic Pharma Analyst Review 2027: Stock at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-analyst-review\/#Shareholding_Trend\" title=\"Shareholding Trend\">Shareholding Trend<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-analyst-review\/#What_to_Watch_After_the_Alembic_Pharma_Analyst_Review_2027\" title=\"What to Watch After the Alembic Pharma Analyst Review 2027\">What to Watch After the Alembic Pharma Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-analyst-review\/#Final_Word_on_the_Alembic_Pharma_Analyst_Review_2027\" title=\"Final Word on the Alembic Pharma Analyst Review 2027\">Final Word on the Alembic Pharma Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-analyst-review\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-analyst-review\/#What_does_the_Alembic_Pharma_analyst_review_2027_show\" title=\"What does the Alembic Pharma analyst review 2027 show?\">What does the Alembic Pharma analyst review 2027 show?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-analyst-review\/#What_is_the_Alembic_Pharma_share_price_target_2027_from_brokerages\" title=\"What is the Alembic Pharma share price target 2027 from brokerages?\">What is the Alembic Pharma share price target 2027 from brokerages?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-analyst-review\/#Why_did_Alembic_Pharma_profit_jump_in_Q2_FY27\" title=\"Why did Alembic Pharma profit jump in Q2 FY27?\">Why did Alembic Pharma profit jump in Q2 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-analyst-review\/#What_is_bosutinib_and_why_does_it_matter_for_Alembic_Pharma\" title=\"What is bosutinib and why does it matter for Alembic Pharma?\">What is bosutinib and why does it matter for Alembic Pharma?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-analyst-review\/#Is_Alembic_Pharma_stock_expensive_based_on_the_Alembic_Pharma_analyst_review_2027\" title=\"Is Alembic Pharma stock expensive based on the Alembic Pharma analyst review 2027?\">Is Alembic Pharma stock expensive based on the Alembic Pharma analyst review 2027?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-analyst-review\/#What_risks_does_the_Alembic_Pharma_analyst_review_2027_highlight\" title=\"What risks does the Alembic Pharma analyst review 2027 highlight?\">What risks does the Alembic Pharma analyst review 2027 highlight?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-analyst-review\/#What_should_investors_track_after_the_Alembic_Pharma_analyst_review_2027\" title=\"What should investors track after the Alembic Pharma analyst review 2027?\">What should investors track after the Alembic Pharma analyst review 2027?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Brokerages_Say_in_the_Alembic_Pharma_Analyst_Review_2027\"><\/span><strong>What Brokerages Say in the Alembic Pharma Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Brokerage<\/th>\n<th>Rating<\/th>\n<th>Target Price<\/th>\n<th>Date<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Motilal Oswal<\/td>\n<td>Neutral<\/td>\n<td>\u20b9845<\/td>\n<td>4 August 2026<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Motilal Oswal kept a Neutral view after the June quarter, valuing the company at 17 times forward earnings for an \u20b9845 target. It noted that the cancer drug bosutinib had 180-day US exclusivity on two strengths until November 2026.<\/p>\n<p>We could not verify a named <strong>brokerage<\/strong> target issued after the November results. The stock now trades about 24% above Motilal Oswal&#8217;s level, so revised notes will be the next test for this Alembic Pharma analyst review 2027.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Q2_FY27_Results_in_the_Alembic_Pharma_Analyst_Review_2027\"><\/span><strong>Q2 FY27 Results in the Alembic Pharma Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Q2 FY27<\/th>\n<th>Q2 FY26<\/th>\n<th>Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Revenue from operations<\/td>\n<td>\u20b92,603 crore<\/td>\n<td>\u20b91,910 crore<\/td>\n<td>Up 36%<\/td>\n<\/tr>\n<tr>\n<td>EBITDA<\/td>\n<td>\u20b9578 crore<\/td>\n<td>\u20b9323 crore<\/td>\n<td>Up about 79%<\/td>\n<\/tr>\n<tr>\n<td>EBITDA margin<\/td>\n<td>22%<\/td>\n<td>17%<\/td>\n<td>Up 5 points<\/td>\n<\/tr>\n<tr>\n<td>Net profit<\/td>\n<td>\u20b9335 crore<\/td>\n<td>\u20b9184 crore<\/td>\n<td>Up 81%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Revenue rose 36% and <strong>net profit<\/strong> rose 81%, as the <strong>EBITDA margin<\/strong> widened to 22%. Compared with the June quarter, profit rose about 94% and revenue about 21%.<\/p>\n<p>All four businesses grew in double digits. That broad growth, rather than one product alone, is the core finding of this Alembic Pharma analyst review 2027.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_Alembic_Pharma_Makes_Money\"><\/span><strong>How Alembic Pharma Makes Money<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Segment<\/th>\n<th>Q2 FY27 Revenue<\/th>\n<th>Growth<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>US business<\/td>\n<td>\u20b9910 crore<\/td>\n<td>Up 77%<\/td>\n<\/tr>\n<tr>\n<td>India branded<\/td>\n<td>\u20b9725 crore<\/td>\n<td>Up 14%<\/td>\n<\/tr>\n<tr>\n<td>Ex-US international<\/td>\n<td>\u20b9440 crore<\/td>\n<td>Up 12%<\/td>\n<\/tr>\n<tr>\n<td>API<\/td>\n<td>\u20b9436 crore<\/td>\n<td>Up 39%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul>\n<li><strong>US business:<\/strong> the largest segment, boosted by new launches including bosutinib.<\/li>\n<li><strong>India branded:<\/strong> medicines sold to doctors, with specialty and animal health driving growth.<\/li>\n<li><strong>API:<\/strong> active ingredients sold to other drug makers.<\/li>\n<li><strong>Ex-US exports:<\/strong> sales to Europe, emerging markets and other regions.<\/li>\n<\/ul>\n<p>FY26 revenue was about \u20b97,399 crore with profit of about \u20b9671 crore. Within the US business, management said generics grew 72% and the base portfolio grew 23% excluding new launches. These figures shape this Alembic Pharma analyst review 2027.<\/p>\n<p>A 180-day exclusivity period lets the first generic seller earn high prices before rivals enter. Bosutinib&#8217;s exclusivity ends in November 2026, so management factored some normalisation into its raised guidance. How much US sales hold up after that is the biggest single question for the coming quarters.<\/p>\n<p>The company is also expanding its India specialty portfolio. India branded sales rose 14% against a historical growth rate of about 6% a year from FY22 to FY26, and total prescriptions rose to 137.6 million in the year to September 2026 from 133.2 million.<\/p>\n<p>Cash flow is another point to watch. Operating cash flow was about \u20b9783 crore in FY26 after a weak \u20b988 crore in FY25, and <strong>debt to equity<\/strong> is modest at 0.26. A stronger cash position gives Alembic room to fund new plants, research spending and US launches without stretching the balance sheet, which matters as research costs have been rising.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Growth_Triggers_in_the_Alembic_Pharma_Analyst_Review_2027\"><\/span><strong>Growth Triggers in the Alembic Pharma Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Raised guidance:<\/strong> FY27 revenue growth now seen at 20% to 25%, up from mid-teens.<\/li>\n<li><strong>US launches:<\/strong> new products drove 77% US growth.<\/li>\n<li><strong>API momentum:<\/strong> 39% growth with at least high-teens expected for FY27.<\/li>\n<li><strong>India recovery:<\/strong> branded growth of 14%, above its past trend.<\/li>\n<li><strong>Margin gains:<\/strong> <strong>EBITDA<\/strong> margin at 22% supports the Alembic Pharma share price target 2027 case.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_in_the_Alembic_Pharma_Analyst_Review_2027\"><\/span><strong>Key Risks in the Alembic Pharma Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Exclusivity ending:<\/strong> bosutinib&#8217;s 180-day window closes in November 2026.<\/li>\n<li><strong>US price erosion:<\/strong> generic prices fall as more rivals launch.<\/li>\n<li><strong>Regulatory risk:<\/strong> US FDA inspections of plants.<\/li>\n<li><strong>Stock above targets:<\/strong> the last named target is well below the price.<\/li>\n<li><strong>High base:<\/strong> a record quarter sets a tough comparison, a caution in the Alembic Pharma analyst review 2027.<\/li>\n<\/ul>\n<p><strong><a href=\"https:\/\/univest.in\/screeners\">Compare Alembic Pharma With Other Pharma Stocks on the Univest Screener<\/a><\/strong><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Alembic_Pharma_Analyst_Review_2027_Stock_at_a_Glance\"><\/span><strong>Alembic Pharma Analyst Review 2027: Stock at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Value<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Share Price (18 Nov 2026 close)<\/td>\n<td>\u20b91,044.35<\/td>\n<\/tr>\n<tr>\n<td>52-Week High \/ Low<\/td>\n<td>\u20b91,075.00 \/ \u20b9635.80<\/td>\n<\/tr>\n<tr>\n<td>Market Capitalisation<\/td>\n<td>\u20b920,512 crore<\/td>\n<\/tr>\n<tr>\n<td>P\/E (TTM)<\/td>\n<td>24.4<\/td>\n<\/tr>\n<tr>\n<td>Industry P\/E<\/td>\n<td>40.1<\/td>\n<\/tr>\n<tr>\n<td>Price to Book<\/td>\n<td>3.45<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity<\/td>\n<td>14.2%<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.26<\/td>\n<\/tr>\n<tr>\n<td>Dividend Yield<\/td>\n<td>1.15%<\/td>\n<\/tr>\n<tr>\n<td>FY26 Revenue \/ Net Profit<\/td>\n<td>\u20b97,399 crore \/ \u20b9671 crore<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The trailing <strong>P\/E<\/strong> of about 24 is well below the industry figure of about 40, even after the rally. Against the <a href=\"https:\/\/univest.in\/indices\/nifty-pharma\/nifty-pharma-share-price-today\">Nifty Pharma<\/a> index, that gap is the main valuation support in this Alembic Pharma analyst review 2027, though part of recent profit depends on exclusivity sales.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Shareholding_Trend\"><\/span><strong>Shareholding Trend<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Holder<\/th>\n<th>Sep 2025<\/th>\n<th>Sep 2026<\/th>\n<th>Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Promoters<\/td>\n<td>69.74%<\/td>\n<td>69.87%<\/td>\n<td>Up 0.13 points<\/td>\n<\/tr>\n<tr>\n<td>Foreign Investors (FII)<\/td>\n<td>4.05%<\/td>\n<td>4.54%<\/td>\n<td>Up 0.49 points<\/td>\n<\/tr>\n<tr>\n<td>Domestic Institutions (DII)<\/td>\n<td>16.30%<\/td>\n<td>15.43%<\/td>\n<td>Down 0.87 points<\/td>\n<\/tr>\n<tr>\n<td>Public<\/td>\n<td>9.92%<\/td>\n<td>10.15%<\/td>\n<td>Up 0.23 points<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The <strong>promoter<\/strong> group holds about 69.9%, through Nirayu Private Limited at 35.8% and listed group company <a href=\"https:\/\/univest.in\/stocks\/alembicltd\/alembic-ltd-share-price-today\">Alembic Ltd<\/a> at 28.5%. Stable holdings are a neutral point in the Alembic Pharma analyst review 2027.<\/p>\n<p><strong><a href=\"https:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a><\/strong><\/p>\n<p><strong><a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a><\/strong><\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_to_Watch_After_the_Alembic_Pharma_Analyst_Review_2027\"><\/span><strong>What to Watch After the Alembic Pharma Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>US sales after exclusivity:<\/strong> how revenue holds once bosutinib faces rivals.<\/li>\n<li><strong>Guidance delivery:<\/strong> tracking against 20% to 25% FY27 growth.<\/li>\n<li><strong>Margins:<\/strong> <strong>EBITDA<\/strong> margin near 22%.<\/li>\n<li><strong>FDA updates:<\/strong> plant inspection outcomes.<\/li>\n<li><strong>New broker notes:<\/strong> fresh targets would reset the Alembic Pharma share price target 2027 view.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Final_Word_on_the_Alembic_Pharma_Analyst_Review_2027\"><\/span><strong>Final Word on the Alembic Pharma Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <strong>Alembic Pharma analyst review 2027<\/strong> shows a record quarter, with profit up 81%, every segment growing and guidance raised to 20% to 25%. The stock has moved well past the last named target, and the end of bosutinib exclusivity is the key near-term test.<\/p>\n<p>The <strong>Alembic Pharma stock outlook 2027<\/strong> depends on US sales after exclusivity, steady India growth and margins. Univest does not give a buy or sell call.<\/p>\n<div style=\"background:#FFF5F5;border-left:5px solid #C62828;padding:14px 18px;margin:24px 0;\">\n<p style=\"color:#C62828;\"><strong>Disclaimer:<\/strong> This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div class=\"faq-schema\">\n<h3><span class=\"ez-toc-section\" id=\"What_does_the_Alembic_Pharma_analyst_review_2027_show\"><\/span><strong>What does the Alembic Pharma analyst review 2027 show?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>It shows a record quarter. Q2 FY27 revenue rose 36% to \u20b92,603 crore and profit rose 81% to \u20b9335 crore. EBITDA margin improved to 22% from 17%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Alembic_Pharma_share_price_target_2027_from_brokerages\"><\/span><strong>What is the Alembic Pharma share price target 2027 from brokerages?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Motilal Oswal had a Neutral rating with an \u20b9845 target on 4 August 2026. The stock closed at \u20b91,044.35 on 18 November 2026, well above that level. We could not verify a named target issued after the Q2 results.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_did_Alembic_Pharma_profit_jump_in_Q2_FY27\"><\/span><strong>Why did Alembic Pharma profit jump in Q2 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>US business revenue grew 77% to \u20b9910 crore on new launches including bosutinib. API grew 39% and India branded grew 14%. EBITDA margin widened by about 5 points.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_bosutinib_and_why_does_it_matter_for_Alembic_Pharma\"><\/span><strong>What is bosutinib and why does it matter for Alembic Pharma?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Bosutinib is a cancer drug where Alembic had 180-day US exclusivity on two strengths until November 2026. Exclusivity allows higher prices before rivals launch. Management built some normalisation into its raised 20% to 25% guidance.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Alembic_Pharma_stock_expensive_based_on_the_Alembic_Pharma_analyst_review_2027\"><\/span><strong>Is Alembic Pharma stock expensive based on the Alembic Pharma analyst review 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The trailing P\/E is about 24 against an industry P\/E of about 40. Price to book is about 3.45. Part of recent profit depends on exclusivity sales that will fade.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_does_the_Alembic_Pharma_analyst_review_2027_highlight\"><\/span><strong>What risks does the Alembic Pharma analyst review 2027 highlight?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The main risks are the end of bosutinib exclusivity, US price erosion and FDA inspections. The stock trades about 24% above Motilal Oswal&#8217;s \u20b9845 target. The record quarter also sets a high base.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_should_investors_track_after_the_Alembic_Pharma_analyst_review_2027\"><\/span><strong>What should investors track after the Alembic Pharma analyst review 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Track US sales once exclusivity ends and progress against 20% to 25% FY27 growth guidance. Watch EBITDA margin near 22%. New broker targets after the results also matter.<\/p>\n<\/div>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What does the Alembic Pharma analyst review 2027 show?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"It shows a record quarter. Q2 FY27 revenue rose 36% to \u20b92,603 crore and profit rose 81% to \u20b9335 crore. EBITDA margin improved to 22% from 17%.\"}},{\"@type\":\"Question\",\"name\":\"What is the Alembic Pharma share price target 2027 from brokerages?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Motilal Oswal had a Neutral rating with an \u20b9845 target on 4 August 2026. The stock closed at \u20b91,044.35 on 18 November 2026, well above that level. We could not verify a named target issued after the Q2 results.\"}},{\"@type\":\"Question\",\"name\":\"Why did Alembic Pharma profit jump in Q2 FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"US business revenue grew 77% to \u20b9910 crore on new launches including bosutinib. API grew 39% and India branded grew 14%. EBITDA margin widened by about 5 points.\"}},{\"@type\":\"Question\",\"name\":\"What is bosutinib and why does it matter for Alembic Pharma?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Bosutinib is a cancer drug where Alembic had 180-day US exclusivity on two strengths until November 2026. Exclusivity allows higher prices before rivals launch. Management built some normalisation into its raised 20% to 25% guidance.\"}},{\"@type\":\"Question\",\"name\":\"Is Alembic Pharma stock expensive based on the Alembic Pharma analyst review 2027?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The trailing P\/E is about 24 against an industry P\/E of about 40. Price to book is about 3.45. Part of recent profit depends on exclusivity sales that will fade.\"}},{\"@type\":\"Question\",\"name\":\"What risks does the Alembic Pharma analyst review 2027 highlight?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The main risks are the end of bosutinib exclusivity, US price erosion and FDA inspections. The stock trades about 24% above Motilal Oswal's \u20b9845 target. The record quarter also sets a high base.\"}},{\"@type\":\"Question\",\"name\":\"What should investors track after the Alembic Pharma analyst review 2027?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Track US sales once exclusivity ends and progress against 20% to 25% FY27 growth guidance. Watch EBITDA margin near 22%. New broker targets after the results also matter.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Alembic Pharma grew Q2 FY27 revenue 36% and profit 81% to \u20b9335 crore, led by a 77% jump in US sales, and raised FY27 growth guidance to 20% to 25%. The stock has run past Motilal Oswal&#8217;s \u20b9845 target. We review results, segments, valuation and risks.<\/p>\n","protected":false},"author":38,"featured_media":355058,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[24444,10050,4341,6686],"class_list":["post-355059","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-24444","tag-alembic-pharmaceuticals","tag-analyst-review","tag-pharmaceuticals"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["355058"],"rank_math_title":["Alembic Pharma Share Price Target 2027: Q2 Review"],"rank_math_description":["Alembic Pharma analyst review 2027: Q2 FY27 profit up 81% to \u20b9335 crore, US sales up 77%, FY27 growth guidance raised to 20-25%, Motilal Oswal \u20b9845 and risks."],"rank_math_focus_keyword":["Alembic Pharma analyst review 2027"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/alembic-pharma-analyst-review-2027-profit-up-81-and-guidance-raised-stock-runs.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/355059","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=355059"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/355059\/revisions"}],"predecessor-version":[{"id":355060,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/355059\/revisions\/355060"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/355058"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=355059"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=355059"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=355059"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}